Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer
I'm PortAI, I can summarize articles.
Natera Inc. and MEDSIR have launched the MiRaDoR phase II clinical trial for HR+/HER2- breast cancer, using Natera's Signatera Genome technology to evaluate treatment effectiveness. The trial aims to set a new standard in precision oncology by assessing treatment combinations' ability to reduce circulating-tumor DNA. Supported by F. Hoffman-La Roche Ltd., the trial is enrolling patients across multiple sites, with plans for expansion in Europe.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments